203 related articles for article (PubMed ID: 15251260)
1. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease.
Gillies GE; Murray HE; Dexter D; McArthur S
Pharmacol Biochem Behav; 2004 Jul; 78(3):513-22. PubMed ID: 15251260
[TBL] [Abstract][Full Text] [Related]
2. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens.
Gillies GE; McArthur S
Horm Behav; 2010 Jan; 57(1):23-34. PubMed ID: 19538962
[TBL] [Abstract][Full Text] [Related]
3. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females.
Murray HE; Pillai AV; McArthur SR; Razvi N; Datla KP; Dexter DT; Gillies GE
Neuroscience; 2003; 116(1):213-22. PubMed ID: 12535954
[TBL] [Abstract][Full Text] [Related]
4. Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice.
Anderson LI; Leipheimer RE; Dluzen DE
Neuroscience; 2005; 130(2):369-82. PubMed ID: 15664693
[TBL] [Abstract][Full Text] [Related]
5. Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.
McArthur S; Murray HE; Dhankot A; Dexter DT; Gillies GE
J Neurochem; 2007 Feb; 100(3):678-92. PubMed ID: 17116232
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective actions of sex steroids in Parkinson's disease.
Bourque M; Dluzen DE; Di Paolo T
Front Neuroendocrinol; 2009 Jul; 30(2):142-57. PubMed ID: 19410597
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
Crotty S; Fitzgerald P; Tuohy E; Harris DM; Fisher A; Mandel A; Bolton AE; Sullivan AM; Nolan Y
Eur J Neurosci; 2008 Jan; 27(2):294-300. PubMed ID: 18190522
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
9. Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson's disease.
Field EF; Metz GA; Pellis SM; Whishaw IQ
Behav Brain Res; 2006 Nov; 174(1):39-48. PubMed ID: 16930735
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in Parkinson's disease and other movement disorders.
Smith KM; Dahodwala N
Exp Neurol; 2014 Sep; 259():44-56. PubMed ID: 24681088
[TBL] [Abstract][Full Text] [Related]
12. Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
Liu B; Dluzen DE
Neuroendocrinology; 2006; 83(5-6):295-302. PubMed ID: 16926530
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and SERM neuroprotection in animal models of Parkinson's disease.
Morissette M; Al Sweidi S; Callier S; Di Paolo T
Mol Cell Endocrinol; 2008 Aug; 290(1-2):60-9. PubMed ID: 18515001
[TBL] [Abstract][Full Text] [Related]
14. Estrogen and movement disorders.
Kompoliti K
Clin Neuropharmacol; 1999; 22(6):318-26. PubMed ID: 10626091
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease.
Singh S; Ahmad R; Mathur D; Sagar RK; Krishana B
Indian J Exp Biol; 2006 Sep; 44(9):699-704. PubMed ID: 16999024
[TBL] [Abstract][Full Text] [Related]
16. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease.
Leaver KR; Allbutt HN; Creber NJ; Kassiou M; Henderson JM
Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1388-94. PubMed ID: 18785982
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
Vernon AC; Palmer S; Datla KP; Zbarsky V; Croucher MJ; Dexter DT
Eur J Neurosci; 2005 Oct; 22(7):1799-806. PubMed ID: 16197521
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
[TBL] [Abstract][Full Text] [Related]
20. Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.
Bourque M; Dluzen DE; Di Paolo T
Front Neuroendocrinol; 2012 Apr; 33(2):169-78. PubMed ID: 22387674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
